Sign in
JNCE Stock Price, Chart, Stats & News
Jounce Therapeutics, Inc.
Save
Jounce Therapeutics, Inc. (JNCE) does not currently pay a dividend.
98.95M
Market cap
–
Current P/E
–
Forward P/E
JNCE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -63.71% |
Pretax margin | -61.93% |
Net margin | -62.10% |
Effective tax rate | -0.27% |
ROA | -23.96% |
ROE | -25.03% |
D/E | 0.05x |
Interest coverage ratio | – |
JNCE valuation
P/E | – |
P/S | 1.21x |
P/B | 0.53x |
P/CF | -3.36x |
P/FCF | -3.32x |
P/OCF | -3.36x |
PEG | -0.02x |
EV multiple | -4.78x |
About
Jounce Therapeutics, Inc. is an immunotherapy firm currently in the clinical development phase, dedicated to discovering and advancing new cancer treatments. A key asset in its pipeline is vopratelimab, a monoclonal antibody presently in Phase II clinical trials. This therapeutic agent functions by binding to and activating the Inducible T cell CO-Stimulator (ICOS), a specific protein located on the surface of T cells within various solid tumors.
Similar securities
Based on sector and market capitalization
Report issue